Vaccine developed that can beat malaria
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GENEVA (AFP) - Researchers have made a breakthrough in the search for an effective malaria vaccine, the World Health Organisation announced yesterday. Early results from a trial in Tanzania show that a new prototype vaccine, SPf66, releases 'a strong immune response' without undesirable side-effects, the WHO said.
The new drug was developed by Manuel Patarroyo, director of the National Institute of Immunology at the National University in Bogota, Colombia, who passed on the rights to the prototype last May. It has already been tried in Latin America, proving effective against the most lethal form of malaria.
But, the WHO said, the Tanzania tests were 'much more serious'. Inhabitants in the region where they were carried out suffered about 100 times more mosquito bites than in Colombia, with up to 25 bites per night by infected mosquitoes.
Further tests are being carried out in Gambia and Thailand. Still more tests over the next two years could mean an effective vaccine in use by 1998, the WHO said. The cost of the new vaccine could be less than dollars 5 ( pounds 3.40) per injection.
Malaria affects two billion people, but 90 per cent of cases arise in Africa, where it results in up to three million deaths every year, a third of them among under-fives.
The disease is fought with insecticides and treated with drugs, but people who live in malaria-plagued regions cannot take the drugs continually because the parasites become resistant to medication.
Further detailed results of the tests on the prototype will be published in the British medical journal Vaccine on Friday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments